



Market Announcement

21 February 2022

Chimeric Therapeutics Limited (ASX: CHM) – Trading Halt

Description

The securities of Chimeric Therapeutics Limited ('CHM') will be placed in trading halt at the request of CHM, pending it releasing an announcement regarding the outcome of the institutional component of the accelerated entitlement offer. Unless ASX decides otherwise, the securities will remain in trading halt until the commencement of normal trading on Wednesday, 23 February 2022.

Issued by

Alice Montefiore-King

Adviser, Listings Compliance (Sydney)



21 February 2022

Alice Montefiore-King
Compliance Adviser, Listings Compliance (Melbourne)
ASX Compliance Pty Ltd
525 Collins Street, Melbourne, VIC. 3000

Via email: tradinghaltsmelbourne@asx.com.au

Dear Alice

**Chimeric Therapeutics Limited (ASX: CHM)
TRADING HALT REQUEST**

In accordance with ASX Listing Rule 17.1, Chimeric Therapeutics Limited (ASX: CHM) (the **Company**) hereby requests that its securities be placed into an immediate trading halt pending an announcement in relation to a capital raising.

The Company requests that trading in its securities be halted until after the expected announcement is made or until the market opens on 23 February 2022, whichever is the earlier.

The Company is not aware of any reason why this trading halt request should not be granted.

Please contact me if you require any further information.

Yours sincerely

A handwritten signature in black ink, appearing to be 'Phillip Hains', written over a light orange background.

Phillip Hains
Company Secretary